bumetanide has been researched along with Acute Disease in 13 studies
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| " bumetanide (25 micrograms kg-1) were prospectively studied in 24 patients with angiographically documented coronary artery disease and either acute exercise-induced (Group I, n = 12) or chronic (Group II, n = 12) heart failure." | 9.06 | Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure. ( Frais, MA; Muller, P; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1987) |
| "Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF)." | 7.79 | Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. ( Elkayam, U; Han, SY; Hshieh, S; Hyderi, AF; Jeng, AI; Kim, BJ; Konopka, E; Lou, M; Ng, TM; Phan, DH; Tsuji, Y, 2013) |
| "The effect of bumetanide in infants with congenital heart disease presenting with cardiac failure was studied." | 7.65 | Bumetanide in heart failure in infancy. ( Lam, LK; Ward, OC, 1977) |
| "We examined diuretic response (defined as Δ weight kg/40 mg furosemide) in 1745 hospitalized acute heart failure patients from the PROTECT trial." | 5.19 | Diuretic response in acute heart failure: clinical characteristics and prognostic significance. ( Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA, 2014) |
| " bumetanide (25 micrograms kg-1) were prospectively studied in 24 patients with angiographically documented coronary artery disease and either acute exercise-induced (Group I, n = 12) or chronic (Group II, n = 12) heart failure." | 5.06 | Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure. ( Frais, MA; Muller, P; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1987) |
| "Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF)." | 3.79 | Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure. ( Elkayam, U; Han, SY; Hshieh, S; Hyderi, AF; Jeng, AI; Kim, BJ; Konopka, E; Lou, M; Ng, TM; Phan, DH; Tsuji, Y, 2013) |
| "The effect of bumetanide in infants with congenital heart disease presenting with cardiac failure was studied." | 3.65 | Bumetanide in heart failure in infancy. ( Lam, LK; Ward, OC, 1977) |
| "Ischemia-reperfusion acute lung injury is characterized by increased vascular permeability, lung edema, and neutrophil sequestration." | 1.46 | Inhibition of Na-K-Cl cotransporter isoform 1 reduces lung injury induced by ischemia-reperfusion. ( Huang, KL; Lan, CC; Lin, HJ; Peng, CK; Tang, SE; Wu, CP; Yang, SS, 2017) |
| "Hypoalbuminemia is believed to decrease diuretic effectiveness and contribute to diuretic resistance that is observed in patients with nephrotic syndrome." | 1.39 | The effect of continuous infusion loop diuretics in patients with acute decompensated heart failure with hypoalbuminemia. ( Bleske, BE; Clark, MM; Dorsch, MP; Wu, AH, 2013) |
| "During 5 h of acute respiratory acidosis in both groups, the mean PaCO2 increased approximately 25 mm Hg, with comparable changes in CSF PCO2." | 1.29 | Ionic composition of cisternal CSF in acute respiratory acidosis: lack of effect of large dose bumetanide. ( Davis, C; Javaheri, S; Rogers, DH, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleske, BE | 1 |
| Clark, MM | 1 |
| Wu, AH | 1 |
| Dorsch, MP | 1 |
| Ng, TM | 1 |
| Konopka, E | 1 |
| Hyderi, AF | 1 |
| Hshieh, S | 1 |
| Tsuji, Y | 1 |
| Kim, BJ | 1 |
| Han, SY | 1 |
| Phan, DH | 1 |
| Jeng, AI | 1 |
| Lou, M | 1 |
| Elkayam, U | 1 |
| Valente, MA | 1 |
| Voors, AA | 2 |
| Damman, K | 2 |
| Van Veldhuisen, DJ | 1 |
| Massie, BM | 1 |
| O'Connor, CM | 1 |
| Metra, M | 1 |
| Ponikowski, P | 1 |
| Teerlink, JR | 1 |
| Cotter, G | 1 |
| Davison, B | 1 |
| Cleland, JG | 1 |
| Givertz, MM | 1 |
| Bloomfield, DM | 1 |
| Fiuzat, M | 1 |
| Dittrich, HC | 1 |
| Hillege, HL | 1 |
| MacKenzie, G | 1 |
| Maguire, J | 1 |
| Testani, JM | 2 |
| Hanberg, JS | 2 |
| Cheng, S | 1 |
| Rao, V | 1 |
| Onyebeke, C | 1 |
| Laur, O | 1 |
| Kula, A | 1 |
| Chen, M | 1 |
| Wilson, FP | 1 |
| Darlington, A | 1 |
| Bellumkonda, L | 2 |
| Jacoby, D | 1 |
| Tang, WH | 1 |
| Parikh, CR | 1 |
| Lan, CC | 1 |
| Peng, CK | 1 |
| Tang, SE | 1 |
| Lin, HJ | 1 |
| Yang, SS | 1 |
| Wu, CP | 1 |
| Huang, KL | 1 |
| Ter Maaten, JM | 1 |
| Rao, VS | 1 |
| Perry Wilson, F | 1 |
| Assefa, M | 1 |
| Sam Broughton, J | 1 |
| D'Ambrosi, J | 1 |
| Wilson Tang, WH | 1 |
| Ellison, DH | 1 |
| Javaheri, S | 1 |
| Davis, C | 1 |
| Rogers, DH | 1 |
| Varriale, P | 1 |
| Mossavi, A | 1 |
| Ward, OC | 1 |
| Lam, LK | 1 |
| Seth, HC | 1 |
| Coulshed, N | 1 |
| Epstein, E | 1 |
| Rybak, LP | 1 |
| Whitworth, C | 1 |
| Scott, V | 1 |
| Verma, SP | 1 |
| Silke, B | 1 |
| Reynolds, G | 1 |
| Muller, P | 1 |
| Frais, MA | 1 |
| Taylor, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure[NCT04298229] | Phase 3 | 240 participants (Actual) | Interventional | 2020-04-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for bumetanide and Acute Disease
| Article | Year |
|---|---|
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diur | 2014 |
The benefit of low-dose dopamine during vigorous diuresis for congestive heart failure associated with renal insufficiency: does it protect renal function?
Topics: Acute Disease; Acute Kidney Injury; Aged; Aged, 80 and over; Bumetanide; Diuretics; Dopamine; Dose-R | 1997 |
Intravenous bumetanide in the treatment of acute and chronic pulmonary oedema.
Topics: Acute Disease; Bumetanide; Chronic Disease; Clinical Trials as Topic; Diuretics; Female; Humans; Inj | 1975 |
Immediate effects of bumetanide on systemic haemodynamics and left ventricular volume in acute and chronic heart failure.
Topics: Acute Disease; Adult; Aged; Bumetanide; Chronic Disease; Clinical Trials as Topic; Diuretics; Electr | 1987 |
9 other studies available for bumetanide and Acute Disease
| Article | Year |
|---|---|
The effect of continuous infusion loop diuretics in patients with acute decompensated heart failure with hypoalbuminemia.
Topics: Acute Disease; Adult; Aged; Blood Pressure; Blood Urea Nitrogen; Bumetanide; Creatinine; Diuretics; | 2013 |
Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure.
Topics: Acute Disease; Adult; Aged; Blood Urea Nitrogen; Bumetanide; Cohort Studies; Diuretics; Drug Therapy | 2013 |
Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility.
Topics: Acute Disease; Animals; Bumetanide; Chronic Disease; Corticosterone; Disease Models, Animal; gamma-A | 2015 |
Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure.
Topics: Acute Disease; Administration, Intravenous; Aged; Biomarkers; Bumetanide; Drug Monitoring; Drug Resi | 2016 |
Inhibition of Na-K-Cl cotransporter isoform 1 reduces lung injury induced by ischemia-reperfusion.
Topics: Acute Disease; Animals; Bumetanide; Capillary Permeability; Disease Models, Animal; Lung Injury; Mal | 2017 |
Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
Topics: Acute Disease; Administration, Intravenous; Biomarkers; Bumetanide; Dose-Response Relationship, Drug | 2017 |
Ionic composition of cisternal CSF in acute respiratory acidosis: lack of effect of large dose bumetanide.
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Acute Disease; Animals; Blood Pressure; Bumetanide; Ch | 1993 |
Bumetanide in heart failure in infancy.
Topics: Acute Disease; Bumetanide; Diuresis; Diuretics; Heart Defects, Congenital; Heart Failure; Humans; In | 1977 |
Comparative acute ototoxicity of loop diuretic compounds.
Topics: Acute Disease; Animals; Bumetanide; Chinchilla; Cochlea; Diuretics; Dose-Response Relationship, Drug | 1991 |